An investigational SMO inhibitor, taladegib, has demonstrated a potent inhibitory effect on SMO D473H mutant and showed promising antitumor efficacy in Hh treatment-naïve and previously Hh-treated BCC patients, showing promise as second-line therapy for SMO-inhibitor resistant cancers. Here, SMO is linked to cancer.